Baillie Gifford - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.

Quarter-by-quarter ownership
Baillie Gifford ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$43,415
+44.7%
7630.0%0.00%
Q3 2022$30,000
-16.7%
763
-6.4%
0.00%
Q2 2022$36,000
+16.1%
815
+4.6%
0.00%
Q1 2022$31,0000.0%7790.0%0.00%
Q4 2021$31,000
-13.9%
779
-11.5%
0.00%
Q3 2021$36,000
-18.2%
880
-8.5%
0.00%
Q2 2021$44,000
+4.8%
962
-4.4%
0.00%
Q1 2021$42,000
+2.4%
1,006
+5.5%
0.00%
Q4 2020$41,0009540.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders